Armour Thyroid is not FDA approved. The FDA’s own drug database lists it under “marketing status: unapproved drug other,” and its labeling carries a disclaimer stating the drug “has not been found by FDA to be safe and effective.” Despite this, Armour Thyroid remains legally available by prescription in the United States, a situation rooted in a regulatory loophole that dates back nearly a century.
Why It’s Still on the Market Without Approval
When Congress passed the modern Food, Drug, and Cosmetic Act in 1938, it exempted drugs that were already being sold under the earlier 1906 food and drug law. Armour Thyroid, a desiccated (dried and powdered) pig thyroid product, had been in use since the late 1800s. Because it was already on the market before the new approval requirements took effect, it was essentially grandfathered in and never required to go through the formal New Drug Application process that modern medications must complete.
This means Armour Thyroid has never undergone the large-scale clinical trials the FDA normally requires to confirm a drug is safe and effective. It exists in a gray area: legal to prescribe and sell, but without the agency’s official stamp of approval.
How It Differs From Approved Thyroid Drugs
The FDA draws a clear line between the two main types of thyroid replacement therapy. Synthetic levothyroxine (sold as Synthroid, Levoxyl, and other brands) has full FDA approval from multiple manufacturers. Desiccated thyroid extract products, including Armour Thyroid, NP Thyroid, and Nature-Throid, do not.
The difference matters beyond paperwork. FDA-approved levothyroxine contains only T4, one of the two thyroid hormones your body uses. Your body converts T4 into T3 as needed. Armour Thyroid provides both hormones directly: 38 micrograms of T4 and 9 micrograms of T3 per grain. Some patients and practitioners prefer this combination approach, but the fixed ratio comes from pig thyroid tissue rather than being individually calibrated, and the FDA has not evaluated whether this combination delivers consistent, predictable results through formal trials.
The FDA Is Tightening Its Stance
The regulatory landscape for Armour Thyroid and similar products is actively shifting. The FDA now classifies animal-derived thyroid medications as biological products under the Public Health Service Act, not just conventional drugs. This reclassification has practical consequences: these products are no longer eligible for pharmacy compounding, which limits how they can be prepared and dispensed.
In March 2026, the FDA notified manufacturers, importers, and distributors of unapproved animal-derived thyroid medications that it intends to issue guidance on compliance priorities by August 2026. The agency also signaled it will release guidance on what manufacturers would need to submit to obtain formal marketing approval. This suggests the era of Armour Thyroid operating in a regulatory gray zone may be coming to an end, though no enforcement deadline has been set.
What “Unapproved” Means for You
Being unapproved does not mean Armour Thyroid is counterfeit or illegal. It is manufactured to United States Pharmacopeia (USP) standards, prescribed by licensed doctors, and dispensed by regular pharmacies. Millions of patients have taken it over many decades.
What it does mean is that the product has not been through the same rigorous review process as approved alternatives. The FDA has not independently verified its safety profile, its effectiveness compared to other options, or the consistency of its hormone content from batch to batch. The labeling itself states this plainly. For patients who feel well on Armour Thyroid, this distinction may feel academic. But it’s worth understanding, especially as the FDA moves toward requiring formal approval for these products. If new regulatory guidance results in reformulation, supply disruptions, or changes in availability, patients currently taking Armour Thyroid would need to work with their prescriber on alternatives.